vs

Side-by-side financial comparison of Intercontinental Exchange (ICE) and TENET HEALTHCARE CORP (THC). Click either name above to swap in a different company.

TENET HEALTHCARE CORP is the larger business by last-quarter revenue ($5.5B vs $3.7B, roughly 1.5× Intercontinental Exchange). Intercontinental Exchange runs the higher net margin — 39.1% vs 11.7%, a 27.4% gap on every dollar of revenue. On growth, Intercontinental Exchange posted the faster year-over-year revenue change (13.5% vs 9.0%). Intercontinental Exchange produced more free cash flow last quarter ($1.1B vs $367.0M). Over the past eight quarters, Intercontinental Exchange's revenue compounded faster (12.5% CAGR vs 1.5%).

Intercontinental Exchange, Inc. (ICE) is an American multinational financial services company formed in 2000 that operates global financial exchanges and clearing houses and provides mortgage technology, data and listing services. Listed on the Fortune 500, S&P 500, and Russell 1000, the company owns exchanges for financial and commodity markets, and operates 12 regulated exchanges and marketplaces. This includes ICE futures exchanges in the United States, Canada, and Europe; the Liffe future...

Tenet Healthcare Corporation is an American for-profit multinational healthcare services company based in Dallas. Through its brands, subsidiaries, joint ventures, and partnerships including United Surgical Partners International (USPI), the company operates 65 hospitals and over 450 healthcare facilities. Tenet also runs Conifer Health Solutions, which provides healthcare support services to health systems and other clients.

ICE vs THC — Head-to-Head

Bigger by revenue
THC
THC
1.5× larger
THC
$5.5B
$3.7B
ICE
Growing faster (revenue YoY)
ICE
ICE
+4.6% gap
ICE
13.5%
9.0%
THC
Higher net margin
ICE
ICE
27.4% more per $
ICE
39.1%
11.7%
THC
More free cash flow
ICE
ICE
$783.0M more FCF
ICE
$1.1B
$367.0M
THC
Faster 2-yr revenue CAGR
ICE
ICE
Annualised
ICE
12.5%
1.5%
THC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ICE
ICE
THC
THC
Revenue
$3.7B
$5.5B
Net Profit
$1.4B
$644.0M
Gross Margin
Operating Margin
45.4%
15.4%
Net Margin
39.1%
11.7%
Revenue YoY
13.5%
9.0%
Net Profit YoY
76.4%
12.6%
EPS (diluted)
$2.48
$4.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICE
ICE
THC
THC
Q1 26
$3.7B
Q4 25
$3.1B
$5.5B
Q3 25
$3.0B
$5.3B
Q2 25
$3.3B
$5.3B
Q1 25
$3.2B
$5.2B
Q4 24
$3.0B
$5.1B
Q3 24
$3.0B
$5.1B
Q2 24
$2.9B
$5.1B
Net Profit
ICE
ICE
THC
THC
Q1 26
$1.4B
Q4 25
$851.0M
$644.0M
Q3 25
$816.0M
$579.0M
Q2 25
$851.0M
$522.0M
Q1 25
$797.0M
$622.0M
Q4 24
$698.0M
$572.0M
Q3 24
$657.0M
$681.0M
Q2 24
$632.0M
$477.0M
Operating Margin
ICE
ICE
THC
THC
Q1 26
45.4%
Q4 25
39.4%
15.4%
Q3 25
39.0%
16.8%
Q2 25
39.8%
15.6%
Q1 25
37.8%
18.1%
Q4 24
35.5%
16.2%
Q3 24
36.4%
21.3%
Q2 24
36.8%
14.9%
Net Margin
ICE
ICE
THC
THC
Q1 26
39.1%
Q4 25
27.1%
11.7%
Q3 25
27.1%
10.9%
Q2 25
26.1%
9.9%
Q1 25
24.7%
11.9%
Q4 24
23.0%
11.3%
Q3 24
21.7%
13.3%
Q2 24
21.8%
9.3%
EPS (diluted)
ICE
ICE
THC
THC
Q1 26
$2.48
Q4 25
$1.49
$4.22
Q3 25
$1.42
$3.86
Q2 25
$1.48
$3.14
Q1 25
$1.38
$4.27
Q4 24
$1.21
$3.79
Q3 24
$1.14
$4.89
Q2 24
$1.10
$2.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICE
ICE
THC
THC
Cash + ST InvestmentsLiquidity on hand
$863.0M
$2.9B
Total DebtLower is stronger
$20.4B
$13.1B
Stockholders' EquityBook value
$29.5M
$4.2B
Total Assets
$179.2B
$29.7B
Debt / EquityLower = less leverage
689.81×
3.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICE
ICE
THC
THC
Q1 26
$863.0M
Q4 25
$837.0M
$2.9B
Q3 25
$850.0M
$3.0B
Q2 25
$1.0B
$2.6B
Q1 25
$783.0M
$3.0B
Q4 24
$844.0M
$3.0B
Q3 24
$755.0M
$4.1B
Q2 24
$885.0M
$2.9B
Total Debt
ICE
ICE
THC
THC
Q1 26
$20.4B
Q4 25
$13.1B
Q3 25
$13.1B
Q2 25
$13.1B
Q1 25
$13.1B
Q4 24
$13.1B
Q3 24
$12.8B
Q2 24
$12.8B
Stockholders' Equity
ICE
ICE
THC
THC
Q1 26
$29.5M
Q4 25
$28.9B
$4.2B
Q3 25
$28.6B
$4.0B
Q2 25
$28.4B
$3.7B
Q1 25
$28.0B
$4.2B
Q4 24
$27.6B
$4.2B
Q3 24
$27.2B
$3.8B
Q2 24
$26.7B
$3.5B
Total Assets
ICE
ICE
THC
THC
Q1 26
$179.2B
Q4 25
$136.9B
$29.7B
Q3 25
$140.9B
$29.4B
Q2 25
$144.2B
$28.7B
Q1 25
$142.9B
$29.2B
Q4 24
$139.4B
$28.9B
Q3 24
$135.2B
$29.4B
Q2 24
$137.7B
$29.3B
Debt / Equity
ICE
ICE
THC
THC
Q1 26
689.81×
Q4 25
3.10×
Q3 25
3.26×
Q2 25
3.49×
Q1 25
3.13×
Q4 24
3.14×
Q3 24
3.33×
Q2 24
3.67×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICE
ICE
THC
THC
Operating Cash FlowLast quarter
$1.3B
$731.0M
Free Cash FlowOCF − Capex
$1.1B
$367.0M
FCF MarginFCF / Revenue
31.4%
6.6%
Capex IntensityCapex / Revenue
6.6%
Cash ConversionOCF / Net Profit
0.93×
1.14×
TTM Free Cash FlowTrailing 4 quarters
$4.6B
$2.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICE
ICE
THC
THC
Q1 26
$1.3B
Q4 25
$1.3B
$731.0M
Q3 25
$915.0M
$1.1B
Q2 25
$1.5B
$936.0M
Q1 25
$966.0M
$815.0M
Q4 24
$1.5B
$-331.0M
Q3 24
$898.0M
$1.0B
Q2 24
$1.2B
$747.0M
Free Cash Flow
ICE
ICE
THC
THC
Q1 26
$1.1B
Q4 25
$1.1B
$367.0M
Q3 25
$853.0M
$778.0M
Q2 25
$1.4B
$743.0M
Q1 25
$881.0M
$642.0M
Q4 24
$1.3B
$-661.0M
Q3 24
$819.0M
$829.0M
Q2 24
$1.1B
$602.0M
FCF Margin
ICE
ICE
THC
THC
Q1 26
31.4%
Q4 25
35.3%
6.6%
Q3 25
28.4%
14.7%
Q2 25
44.3%
14.1%
Q1 25
27.3%
12.3%
Q4 24
43.3%
-13.0%
Q3 24
27.0%
16.2%
Q2 24
38.7%
11.8%
Capex Intensity
ICE
ICE
THC
THC
Q1 26
Q4 25
5.3%
6.6%
Q3 25
2.1%
5.3%
Q2 25
1.8%
3.7%
Q1 25
2.6%
3.3%
Q4 24
6.4%
6.5%
Q3 24
2.6%
4.2%
Q2 24
2.6%
2.8%
Cash Conversion
ICE
ICE
THC
THC
Q1 26
0.93×
Q4 25
1.50×
1.14×
Q3 25
1.12×
1.83×
Q2 25
1.77×
1.79×
Q1 25
1.21×
1.31×
Q4 24
2.16×
-0.58×
Q3 24
1.37×
1.53×
Q2 24
1.89×
1.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ICE
ICE

Exchanges$2.5B67%
Fixed income and data services$657.0M18%
Mortgage technology$539.0M15%

THC
THC

Other$2.9B52%
Health Care Patient Service$1.4B25%
Equity Method Investment Nonconsolidated Investee Or Group Of Investees$1.2B22%
Health Care Other Sources$56.0M1%

Related Comparisons